

Supplemental Figure 1. Purity of CD4+ and CD19+ cell isolation and viability of CD4+ T cells after culture with metabolic inhibitor drugs. (**A**) Representative flow cytometry plots of whole blood before isolation and post-Rosette Sep CD4+ enrichment (**B**) Representative flow cytometry plots of PBMCs isolated by density centrifugation before isolation and post EasySep CD4+ enrichment (**C**) Representative flow cytometry plots of PBMCs isolated by density centrifugation before isolation and post CD19+ enrichment. (**D**) Representative viability stain of HD CD4+ T cells stimulated with anti-CD3ε/anti-CD28 and treated for 24 h with 2 mM metformin or 100nM of either rotenone, antimycin-a, or oligomycin.



Supplemental Figure 2. IFNα2a dose titration in HD CD4+ T cells and 2 h metformin co-treatment. (**A**) 3 concentrations of IFNα were tested in CD4+ T cells stimulated with anti-CD3ε/anti-CD28 with or without metformin for 24 h and treated with recombinant IFNα2a for the final 2 h (1 IU = 4 pg/mL). The graphs show means and standard deviation of three technical replicates. (**B**) Effect of 2 h metformin and IFNα2a co-treatment on the expression of 6 ISG genes in HD CD4+ T cells (N = 3). Paired t-tests used for (A, B). * $p<0.05$, ** $p<0.01$.

Supplemental Table 1. Primer sequences for gene expression studies and ChiP assays.

qRT-PCR Gene	**Sequence**	**Product (bp)**
MX1 F	AGGCAAGGTCAGTTACCAGG	89
MX1 R	CGATGGCATTCTGGGCTTTATT	
ISG20 F	CACAAGAGCATCCAGAACAGC	63
ISG20 R	CATCGTTGCCCTCGCATCTT	
GBP1 F	GGCTATGGACCAACTGTACTAT	215
GBP1 R	TCAGCTTCAGGGAGTATGTCAG	
IRF7 F	GAGTCTTCTTCCAAGAGCTGGT	68
IRF7 R	GATGGTATAGCGTGGGGAGC	
ISG15 F	GAGAGGCAGCGAACTCATCT	157
ISG15 R	CTTCAGCTCTGACACCGACA	
OASL F	GAAGGTAGTCAAGGTGGGCTC	163
OASL R	CTGGCTTTGCCACATGGTTT	
PPIA F	AGCTGTTTACCCCTGATCGTG	71
PPIA R	CCTTGTCTGCAAACAGAAGGC	
HMBS F	AGAATGAAGTGGACCTGGTTGT	81
HMBS R	AGATGGCTCCGATGGTGAAG	
ChIP Target	**Sequence**	**Product (bp)**
MX1 promoter 1 F	CCACACGCACAGAAGAGGAA	141
MX1 promoter 1 R	TGCATTTCCTGCAAGTCCGT	
MX1 promoter 2 F	CCAGGAGCTAGGTTTCGTTT	118
MX1 promoter 2 R	GCTCTCGCTTCGCCTCTT	
ISG15 promoter 1 F	TACTGCCCTAAACCGAGTGT	178
ISG15 promoter 1 R	TATCGCGCATTCCAGATCCTT	
ISG15 promoter 2 F	CGCCACTTTTGCTTTTCCCT	88
ISG15 promoter 3 R	TTCGGTTTCCCTTTCCCGAG	
Gene Desert 2 F	AGGAGACACCTTGACTCCCAT	126
Gene Desert 2 R	ACTGATCACGGGGTTACAGC	